Explore the latest from Tr1X.

A collection of publications, press releases, and interviews covering our research, progress, and partnerships.

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

  • Videos
Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles
Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a case study in overcoming cell therapy manufacturing and regulatory hurdles".
  • Videos
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy

  • Press Releases
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered

  • Press Releases
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered

  • Press Releases
NextGen: Class of 2025

BioSpace is proud to present its NextGen: Class of 2025, a list of the hottest new life sciences companies in the United

  • Press Releases
Tr1X to Participate at Upcoming Healthcare Investment Conferences

SAN DIEGO, Sept. 13, 2024 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a biopharmaceutical company specializing in allogeneic engineered Treg

  • Press Releases
Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease.

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a biopharmaceutical company specializing in allogeneic engineered Treg

  • Press Releases
Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases

  • Publications
Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a biopharmaceutical company developing engineered Treg and CAR-Treg

  • Press Releases
Opportunities for Treg cell therapy for the treatment of human disease

Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity, and limiting chronic inflammatory diseases. This small CD4+

  • Publications
Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an Allogeneic Regulatory T-Cell Therapy to Treat Autoimmune Diseases

SAN DIEGO, April 10, 2024 /PRNewswire/ — Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the

  • Press Releases
Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting

Tr1x launched from stealth Wednesday with $75 million to tackle graft-versus-host disease in addition to inflammatory and autoimmune conditions.

  • Interviews
Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases

SAN DIEGO, Jan. 17, 2024 /PRNewswire/ — Tr1X, Inc. today announced its emergence from stealth with a $75 million Series

  • Press Releases